Workflow
Medtronic(MDT)
icon
Search documents
Does the S&P 500 Rally Make MDT Stock a Buy Amid Easing Trade Tension?
ZACKS· 2025-03-25 17:35
The broader market rally, which pushed the benchmark to a two-week record high yesterday, fueled by tech giants like NVIDIA and Tesla, has provided a much-needed breather for investors. This has potentially set the stage for stocks like Medtronic (MDT) to gain momentum.Over the past couple of months, Medtronic’s stock performance has remained sluggish, declining by 0.8%, reflecting the broader industry trend amid challenges such as aggressive tariff policies, trade tensions, and inflationary pressures. Duri ...
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic
ZACKS· 2025-03-25 08:11
For Immediate ReleasesChicago, IL – March 25, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Boston Scientific (BSX) , Abbott (ABT) and Medtronic (MDT) .Here are highlights from Tuesday’s Analyst Blog:Amid Stagnation Fears, Boston Scientific Is a Buy on Growth FactorsBoston Scientific is experiencing a temporary ...
Medtronic (MDT) Up 5.6% Since Last Earnings Report: Can It Continue?
ZACKS· 2025-03-20 16:35
It has been about a month since the last earnings report for Medtronic (MDT) . Shares have added about 5.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Medtronic due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns ...
Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy
Seeking Alpha· 2025-03-20 01:41
Core Insights - The article discusses the investment potential of a specific company, highlighting its strong market position and growth prospects [1][2]. Company Analysis - The company has demonstrated a beneficial long position in its shares, indicating confidence in its future performance [1]. - The analysis emphasizes the company's financial health and strategic initiatives that could drive future growth [1]. Industry Context - The broader industry trends are favorable, with increasing demand for the company's products and services, positioning it well for future expansion [1]. - Competitive landscape analysis suggests that the company is well-positioned against its peers, leveraging its strengths to capture market share [1].
Why Medtronic (MDT) is a Top Momentum Stock for the Long-Term
ZACKS· 2025-03-18 14:50
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The ...
展台直击!36家械企亮点速览 | 2025医学装备大会
思宇MedTech· 2025-03-18 10:14
合作伙伴征集:2025全球手术机器人大会 报名:首届全球眼科大会 | 暂定议程 报名:首届全球心血管大会 | 奖项报名倒计时 报名:首届全球骨科大会 | 奖项报名倒计时 2025年3月15日上午,2025中国医学装备大会在重庆悦来国际会议中心成功召开。相关政府部门领导、知名院士、医疗机构专家,研发生产企业、高校、科 研院所、投融资机构负责人等嘉宾出席大会。 中国医学装备协会理事长 侯岩介绍, 2024年中国医学装备市场规模达到 1.35万亿 元,同比增长 6% 左右 。据了解,目前我国已形成22个大类1100多个 品类的产品体系,是世界上产品类别和品种最齐全的国家之一,产品广泛服务于临床应用,覆盖卫生健康各个领域。 目前大会已圆满落幕。本届展会中,哪些企业凭借创新亮相引起了行业关注?又有哪些前沿产品和技术成为焦点?思宇将全面回顾展会精彩亮点,供各位读 者参考。 # 美敦力 美敦力在本届大会上展出 近80款 全球创新产品, 包括 全球首发的PulseSelect一次性心脏脉冲场消融导管 ,以及多款前沿技术产品, 其中不乏首次展出及近 期获批的产品和技术。 其中包括中国首款获批的 PulseSelect一次性心脏 ...
Positive Trial Data on Evolut TAVR Likely to Support MDT Stock
ZACKS· 2025-03-10 13:40
Medtronic plc (MDT) recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN (“SMART”) Trial results at the Cardiovascular Research Technologies (“CRT”) 2025 conference in Washington, D.C. SMART trial is the largest international head-to-head comparative trial of transfemoral transcatheter aortic valve replacement ("TAVR"), conducted in patients with aortic stenosis ("AS") and a small aortic annulus. The two-year results highlighted the continued superior performance of the Evolut TAVR valve i ...
2025医学装备大会抢先看!38家企业大盘点:美敦力、赛诺威盛、精锋……
思宇MedTech· 2025-03-10 10:31
合作伙伴征集:2025全球手术机器人大会 报名:首届全球眼科大会 | 暂定议程 报名:首届全球心血管大会 | 奖项报名倒计时 报名:首届全球骨科大会 | 奖项报名倒计时 在医疗科技深度融合临床实践的当下,医学装备行业正经历技术与应用的双重跃迁。从精准诊断到微创治疗,从智能康复到个性化医疗,医学装备的每一次 技术突破都直接影响着医疗质量与患者预后。然而,行业的高速发展不仅带来了创新机遇,也伴随着标准化、适应性落地和成本控制等多重挑战。 在这一背景下, 2025中国医学装备大会暨医学装备展览会 成为观察行业动向的重要窗口。2025年3月13日至16日,重庆国际博览中心将汇聚 800多家企 业 ,展示超过 1000件创新产品 。这不仅是一场技术竞演,更是对医疗装备未来走向的深度探讨——哪些技术能够真正提升临床价值?国产创新如何突破市 场壁垒?政策与产业如何协同推动高质量发展?答案,或将在这次行业盛会上逐步揭晓。 # 会议信息 此次参会的龙头企业包括 强生、雅培、美敦力、直观复星、上海微创机器人、迈瑞医疗、东软医疗、GE医疗、西门子医疗、飞利浦、罗氏、碧迪医疗 等。 34大 专业展区,覆盖了从基础到前沿的每一个细分领 ...
SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients
Prnewswire· 2025-03-09 18:00
Core Insights - The SMART Trial presents the two-year results of the largest international head-to-head randomized control trial comparing Evolut and SAPIEN TAVR devices, primarily enrolling women with small aortic annuli [1][3][4] - Evolut TAVR demonstrated superior valve performance and significantly less bioprosthetic valve dysfunction (BVD) compared to SAPIEN TAVR, which is critical for patients with small aortic annuli [2][4][6] Company Overview - Medtronic plc is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [6] - The company employs over 95,000 people across 150 countries, focusing on innovative technologies that address challenging health problems [6][7] Industry Context - Aortic stenosis affects approximately 1.5 million people in the U.S., with a significant portion of the global market having small aortic annuli, necessitating tailored valve selection [5] - The SMART Trial's findings are expected to inform and personalize treatment decisions for patients with symptomatic severe aortic stenosis [2][4]
Medtronic announces cash dividend for fourth quarter of fiscal year 2025
Prnewswire· 2025-03-06 21:30
GALWAY, Ireland, March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend ...